The state of the fight:Moderna shared new Phase 2/3 data supporting the use of Spikevax in children under age 6.
Pfizer will supply UNICEF with up to 4 million Paxlovid courses in 2022.
Boosters of mRNA vaccines continued to offer strong protection against severe Covid-19 outcomes. AUTHORIZED VACCINES
Moderna claimed clinical trial success for its vaccine in children ages 6 months to under 6 years. An interim analysis of Phase 2/3 results showed a “…